Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Chronic Lymphocytic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Chronic Lymphocytic Leukemia. Browse Chronic Lymphocytic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 22, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
107
Shown on this page
11
Current sort
Recently updated
Condition scope
Chronic Lymphocytic Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Chronic Lymphocytic Leukemia studies are organized in the registry

CLL is registered together with small lymphocytic lymphoma (SLL) in many records — they are treated as one disease in study design — so listings often carry both names. Drug-class abbreviations, particularly BTK and BCL-2 inhibitor terms, appear directly in current titles.

Terms that often appear in related listings
SLL BTK inhibitor relapsed CLL venetoclax

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Chronic Lymphocytic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Recognized from query: venetoclax. Matching terms were moved into the structured fields above when recognized.
Showing 97–107 of 107 matching trials for Chronic Lymphocytic Leukemia.
Live ClinicalTrials.gov results.
Active filters: "venetoclax" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Withdrawn Phase 2 Interventional

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

NCT05209308
View directory record Official record
Conditions
CLL
Interventions
Zandelisib, Rituximab, Venetoclax
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

NCT02141282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 22, 2026, 3:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

NCT01328626
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
ABT-199
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
8
States / cities
Tucson, Arizona • La Jolla, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Tafasitamab, Idelalisib, Venetoclax
Biological · Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

NCT03045328
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Duarte, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
CC-122, Ibrutinib, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01671904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Obinutuzumab, Rituximab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

NCT01685892
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Obinutuzumab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
La Jolla, California • Denver, Colorado • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 22, 2026, 3:51 PM EDT
Withdrawn Phase 1 Interventional

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

NCT02640833
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Harvey, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 22, 2026, 3:51 PM EDT

About this Chronic Lymphocytic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Chronic Lymphocytic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Chronic Lymphocytic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Chronic Lymphocytic Leukemia.